Kaleido Biosciences, Inc.
- Jurisdiction
United States - ISIN
US4833471000 (KLDO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
1
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. Read full profile
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
€0.00 - EBIT margin
0.0% - Net income
€0.00 - Net margin
0.0%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 15, 2020 (Q1 2020)